The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025. “The approval of VYKAT XR is a significant milestone for Soleno and, most importantly, for the PWS community who have had ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA ...

Soleno Therapeutics (SLNO) stock jumped over 32% in yesterday’s after-hours trading. The surge came after the company ...

Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.

(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...